Oxombre, B.; Madouri, F.; Journé, A.-S.; Ravez, S.; Woitrain, E.; Odou, P.; Duhal, N.; Ninni, S.; Montaigne, D.; Delhem, N.;
et al. Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis. Int. J. Mol. Sci. 2022, 23, 11893.
https://doi.org/10.3390/ijms231911893
AMA Style
Oxombre B, Madouri F, Journé A-S, Ravez S, Woitrain E, Odou P, Duhal N, Ninni S, Montaigne D, Delhem N,
et al. Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis. International Journal of Molecular Sciences. 2022; 23(19):11893.
https://doi.org/10.3390/ijms231911893
Chicago/Turabian Style
Oxombre, Bénédicte, Fahima Madouri, Anne-Sophie Journé, Séverine Ravez, Eloise Woitrain, Pascal Odou, Nathalie Duhal, Sandro Ninni, David Montaigne, Nadira Delhem,
and et al. 2022. "Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis" International Journal of Molecular Sciences 23, no. 19: 11893.
https://doi.org/10.3390/ijms231911893
APA Style
Oxombre, B., Madouri, F., Journé, A.-S., Ravez, S., Woitrain, E., Odou, P., Duhal, N., Ninni, S., Montaigne, D., Delhem, N., Vermersch, P., & Melnyk, P.
(2022). Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis. International Journal of Molecular Sciences, 23(19), 11893.
https://doi.org/10.3390/ijms231911893